Free in solution, the immunosuppressive compounds cyclosporin A (CsA), FK506, ascomycin and rapamycin are present in many solvents in various slowly interconverting conformations. Together with their cellular receptor proteins, cyclophilin (CyP) and FK506-binding protein (FKBP), however, these inhibitors have been shown to have a homogeneous conformation. The existence of a slow cis-trans interconversion of an imidic bond in the inhibitor molecule during the course of the formation of the CsA-CyPI8cy complex (where CyPl8cy is human 18 kDa cytosolic CyP) prompted us to investigate the reaction of the peptidomacrolides FK506, ascomycin and rapamycin with two specific binding-proteins in more detail. Since formation of the FK506-FKBP complex results in the inhibition of the peptidylprolyl cis-trans-isomerase activity of the binding protein, we used the enzyme's decrease in enzymic activity to monitor binding of the inhibitors to their enzyme targets. For FK506, the kinetics of inhibition of human 12 kDa cytosolic FKBP (FKBP12cy) were clearly dependent on time. Subsequent to a rapid inactivation reaction, not resolved in its kinetics due to manual mixing, a slow dominant first-order inactivation process with a relaxation time of 1163 s at 10°C was observed. Concomitantly the K1 value of the slow phase dropped 2.6-fold within the first 60 min of incubation. Using the FKBP12cy homologue 25 kDa membrane FKBP (FKBP25mem), a bacterial peptidylprolyl cis-trans-isomerase, the rate and amplitudes of the inhibition reactions were very similar to FKBP12cy. On the other hand, the kinetics and amplitudes of the inhibition of FKBP12cy varied significantly if rapamycin was used as an inhibitor instead of FK506. Owing to reduced conformation transition in rapamycin upon binding to FKBP12cy, the slow phase during inhibition was significantly decreased in amplitude. A likely reason for this became apparent when the activation-enthalpy and the pHdependence of the rate constants of the slow phase were determined. We conclude that the cis to trans interconversion of the pipecolinyl bond of the three peptidomacrolides may be responsible for the slow process. There was no indication of a suicide catalysis of this process by FKBPs.
INTRODUCTION
Peptidylprolyl cis-trans-isomerases (PPlases, EC 5.2.1.8) very efficiently catalyse the reversible cis-trans interconversion of a number of imidic peptide bonds arranged within an oligopeptide chain in either direction. The enzymes act specifically on prolinecontaining stretches in polypeptides, which results in an acceleration of protein folding in refolding experiments under suitable conditions (Schmid, 1993) . Thus they represent an important functional group in the rapidly growing class of folding helper-proteins for protein folding reactions. The two structurally unrelated families of PPlases known to date, the cyclophilins (CyP) and the FK506-binding proteins (FKBPs), are ubiquitously distributed and highly conserved in a core region of the amino acid sequence during evolution (for a recent review see Galat, 1993) . Furthermore, the cytosolic members, human 18 kDa cytosolic CyP (CyP18cy) and human 12 kDa cytosolic FKBP (FKBP12cy) are highly abundant within cells and tissues, e.g. about 20,M FKBP12cy in T-lymphocytes (Siekierka et al., 1991) and at least 4,uM CyP18cy in human erythrocytes (Akagi et al., 1991) . Both types of inhibitor molecules contain N-acyl, N-alkyl peptide bonds adjacent to further putative binding sites. These structures may be accompanied by a certain degree of topochemical equivalence to natural, proline-containing substrates not hitherto identified. Since it became clear that the suppression of the T-cell answer after stimulation may arise from the chemical properties of the immunosuppressant-enzyme complexes, detailed knowledge of the course of binding of the inhibitors to PPlases is required.
The structures of CsA in the crystal and in solution (CDC13 C6H6: Kessler et al., 1985; tetrahydrofuran (THF) : Ko and Dalvit, 1992; LiCl-THF: Kock et al., 1992 ; dimethyl sulphoxide (DMSO), CH30H and 50 % (v/v) CH30H/H20: Ko and Dalvit, 1992) were determined. When complexed to CyPl8cy, CsA is uniformly bound (Fesik et Figure 1 Structures of FK506, ascomycin and rapamycin al., 1990) but differs strongly in its conformation from any one of the uncomplexed molecules characterized in the structural investigations. Furthermore, in contrast to the homogeneously bound conformation of CsA, structural diversity due to the presence of cis and trans conformational isomers with respect to the N-methyl-L-leucine9-N-methyl-L-leucine'0 (MeLeu9-MeLeu10) peptide bond was described for most of the CsA solutions .
On the basis of this knowledge, the multiphasic time course of the inactivation of CyPl 8cy by CsA was found to be due to ratelimiting rearrangements of the initial enzyme-inhibitor complex to a tighter one in the final state. In each case only trans MeLeu9-MeLeu'0 is extracted by the enzyme from the multiple conformational equilibrium present in the assay, because the cis isomer has no or reduced affinity for the enzyme (Kofron et al., 1992) .
Likewise, structural investigations of FK506 show the aketoacyl-pipecolinyl moiety either in cis (Tanaka et al., 1987) or, as in chloroform, in a 2: 1 ratio of cis to trans conformation (Karuso et al., 1990) . Rapamycin on the contrary prefers the trans conformation in the crystal (Swindells et al., 1978) . But the FKBP12cy template forces both FK506 and rapamycin to a homogeneously bound conformation with the imidic bond in the trans form and a nearly superimposable structure for the common binding region of both of the macrolides (Van Duyne et al., 1991 . Therefore considerable reorganization of the conformation of FK506 upon binding may be inferred from the different structure of FK506 in apolar solvents and in complex with FKBP12cy.
However, there was no evidence of a slow kinetic phase during the course of FKBP12cy's inhibition by FK506 (Harrison and Stein, 1990; Spencer et al., 1993) . Recently, Petros et al. (1993) with an N-terminal extension consisting of the first eight Nterminal amino acids of the ,-galactosidase, followed by four histidines and an enterokinase cleaving-site for complete elimination of the fusion peptide. The cells (83 g) were resuspended in 330 ml of buffer (20 mM Hepes/l mM EDTA/1 mM dithioerythritol, pH 7.5) and disrupted at 1200 x 105 Pa followed by precipitation with 5.7% (v/v) polymin P (10% neutralized polymin P solution) while being stirred on ice. The supernatant was incubated with DNAase I (0.1 mg/ml DNAase I (Boehringer Mannheim)/6 mM MgCl2) for 30 min at 20°C followed by precipitation with 80 % ammonium sulphate. The dissolved pellet was applied to a size-exclusion column (Sephacryl S-200 HR, 5 cm x 150 cm, 20 mM Hepes/0.2 M NaCl, pH 7.5,190 ml/ h). Fractions with PPIase activity were pooled and applied to an Ni2+-chelating-Sepharose column (5 x 4.6 cm, equilibrated in 20 mM Hepes, pH 7.5, 4 ml/min). A 1800 ml linear gradient of histidine (0-10 mM) in buffer was used to elute the protein. The yield of purified fusion-protein was 708 mg (1.47 mg/ml). An aliquot of 50 mg of fusion-protein was cleaved by enterokinase (Boehringer Mannheim) (100: 1, w/w) for 72 h at 20°C in 20 mM Hepes, pH 7.5. The reaction was stopped by dialysis against 20 mM sodium phosphate, pH 6.5, and native FKBP12cy without N-terminal fusion-peptide was obtained by negativeelution on a hydroxylapatite column (3 cm x 5.6 cm) equilibrated in 20 mM sodium phosphate, pH 6.5. Purified FKBP12cy (25 mg) was analysed by SDS/PAGE, reverse-phase h.p.l.c. and automatic N-terminal sequencing. The protein was more than 99 % pure and showed a homogeneous N-terminus starting with Met-Gly-Val-Gln-Val-.
The concentration of the mature FKBP12cy was determined spectrophotometrically (e28o = 9530 M-' cm-', calculated from the amino acid sequence (Gill and von Hippel, 1989 ) and confirmed by a titration of FK506 binding-sites monitored by fluorescence. Several mixtures of 4,M FKBP12cy (determined spectrophotometrically as described above) with FK506 in the range 0-6 ,M were prepared and incubated for 60 min before measuring. Saturation was achieved at 4,M FK506. Both of the methods for determining the concentration of FKBP12cy showed the same result.
The PPIase activity of the recombinant protein was assayed as described below using the peptide Suc-Ala-Leu-Pro-Phe-pNA 
Solvents, inhibitors and substrates
Anhydrous THF and LiCl were obtained from Aldrich (Steinheim, Germany). LiCl was additionally dried by heating to 150°C under vacuum for 5 h. All other materials were of reagent grade and were used without further purification. FK506, rapamycin and ascomycin were kindly provided by Dr. A. Lawen, Monash University, Clayton, Australia. Stock solutions of FK506 (0.04 mM-2 mM) were prepared in 50 % (v/v) aqueous ethanol, anhydrous DMSO, anhydrous THF and 0.47 M LiCl in THF. The solution of LiCl-THF was made under an argon atmosphere. The peptide substrates Suc-Ala-Xaa-Pro-Phe-pNA (Xaa = Leu, Phe) were purchased from Bachem (Heidelberg, Germany) and Suc-Ala-Ala-Pro-Phe-pNA was obtained from Boehringer Mannheim and used without further purification. Peptide substrate (14 mg/ml) were dissolved in DMSO and diluted 1:10 in assay buffer (1.4 mg/ml) before use to decrease the final concentration of DMSO in the assay.
PPlase assays
To test the PPIase activity the assay of Fischer et al. (1984) was modified. In a typical kinetic experiment, a stock solution of FKBP12cy (3.44 ,uM, 120 ,1) was added to the thermally equilibrated buffer at 10°C (8400 ,ud; 100 mM Tris/HCl, pH 8.0 at 10°C). Inhibitor dissolved in the respective solvent (2 ,ul) was added to final concentrations of 10 nM-40 nM. The components were mixed and subsequently aliquots (710,ul) of the enzymeinhibitor mixture were withdrawn at various preincubation times.
Residual PPIase activity was assayed after addition of 120 Al of a-chymotrypsin (0.55 mM) (Boehringer Mannheim) and 30 ,ul of peptide substrate (1.4 mg/ml).
First data-points for residual activity are available after 1 min because the dead-time of the experiment is the sum of mixing the solution in the preincubation mixture and the dead-time of the subsequent enzyme assay. The reaction progress was monitored for < 3 min by sampling the increase in A390 that accompanies the hydrolysis of the anilide bond, using a Hewlett-Packard 8452A diodearray spectrophotometer equipped with a thermostated cell-holder. The spectrophotometer was interfaced to a model 300 Hewlett-Packard Chemstation computer. Sampled absorbance data-points (typically 50-100 data-pairs) were fitted according to a first-order rate law using Hewlett-Packard kinetic software. Only traces showing strict first-order dependence were used.
The calculation of the Y. values was carried out by non-linear fitting of the data according to a competitive tight-binding equation (eqn. 1) (Morrison and Walsh, 1988) using Sigma Plot software (Jandel Scientific).
This equation includes the condition that the initial concentration of the PPIase substrate in the cis conformation is negligible compared with the Km value and considers the uncatalysed background reaction. Eo and I, are the concentrations of enzyme and inhibitor, and k and kunc are the observed first-order rate constants ofthe progress curves for the catalysed and uncatalysed cis to trans isomerization of the PPIase substrate. The kcat./Km value was determined as described above. The FK506 concentration is based on the determination by weight and is related to both inactive and active conformers.
To determine the pH-dependence of the time-dependent inhibition, buffers were kept at constant ionic strength (Park et al., 1992) .
All data-points are averaged from three independent measurements. Residual PPIase activity was determined relative to a control sample treated identically but devoid of inhibitor.
RESULTS

Time-dependent Inhibitlon of FKBPs by FK506 and ascomycin
The tight-binding inhibitor FK506 and the FKBP12cy are known to form a reversible, stoichiometric complex (1: 1) which results in inactivation of the PPIase activity characterized by a K4 of 1.7 nM (Harrison and Stein, 1990 ). FKBP's loss of enzymic activity was therefore used to investigate the kinetics of the assembly of the protein with peptidomacrolides. An excess of 50 mM FKBP12cy was incubated with 26 nM FK506 delivered from a stock solution in ethanol/water (1: 1, v/v). The remaining activity ofthe enzyme was discontinuously determined depending on incubation time, monitoring the cis to trans interconversion of a proline-containing oligopeptide in the assay. When the inhibition of the PPIase activity of FKBP12cy increases during preincubation in the presence of FK506 then this should result in a decrease in the inhibition constant K1. As illustrated in Figure 3 , prolongation of the incubation time to 60 min leads to enhanced potency of the inhibitor. The initial K, value decreases from 1.3 + 0.5 nM to K final = 0.5 +0.3 nM after 60 min preincubation.
In a similar kinetic experiment we used ascomycin instead of FK506 as an inhibitor of FKBP12cy. This homologue of FK506 is nearly as potent as the parent compound in immunosuppression (Organ et al., 1993) and does not significantly differ from FK506 when bound to FKBP12cy (Petros et al., 1991 Figure 2 the inhibition of FKBP25mem by FK506 was rather similar to the human enzyme. The first-order rate constant kobs and ratio of amplitudes r were determined to be (7.7 + 0.9) x 10s-1 and 0.91, respectively. Obviously the slow phase of inhibition is indepenndent of the enzyme and is caused solely by a structural change, within the inhibitor.
Further support for an enzyme-independent reaction pathway of the slow inactivation process was obtained by investigating the dependence of inhibition kinetics upon varying enzyme and ligand concentrations. If the FK506 interconversion is a nonenzymic, monomolecular process, then the first-order rate constant of the slow reaction should be independent of the enzyme and inhibitor concentrations. Neither changes of the FKBP12cy concentration in the range 20 nM-40 nM in the preincubation mixture nor changes of the FK506 concentration (13 nM-40 nM) yielded any systematic deviation from the mean value of kobS = 8.4 x 10-4 s-1, and the ratio of amplitudes r fluctuated within the limit or error (r = 0.72).
For CsA it was shown that solvents have great influence on the type and quantity of conformers in solution (Kofron et al., 1992; Kessler et al., 1985 Kessler et al., , 1990 Ko and Dalvit, 1992; Kock et al., 1992) . Delivering CsA from stock solutions prepared in various solvents leads to considerable differences in the kinetic pattern of the inhibition. To probe for similar effects of the FK506-FKBP12cy reaction we investigated the inhibition kinetics of FK506 dissolved in 50 % (v/v) aqueous ethanol, DMSO, THF and 0.47 M LiCl-THF before injection into the aqueous assay mixture. Non-aqueous solutions of Li+ salts are known to affect specifically the thermodynamics of cis-trans isomerism of imide bonds (Kofron et al., 1991 (Kofron et al., , 1992 Kock et al., 1992 (Seebach et al., 1994) . The identical amplitudes of the slow phases in the absence and presence ofLiCl presumably indicate that the conformational changes detected in the n.m.r. experiments were due to Li+-perturbation of the inhibitor's imide bond.
Time-dependent inhibition of FKBP by rapamycin Although structurally related to FK506 in the FKBP12cy-binding region, rapamycin differs from the structure of FK506 in several important aspects. Even in the crystal (Swindells et al., 1978) and in DMSO solution (Kessler et al., 1993 ) the structure of rapamycin is virtually identical with the conformation bound to FKBP12cy. Unlike unbound FK506, the predominant rapamycin Figure 4 Eyring plot for the first-order rate constants of the slow phase of inactivation
The time-dependent inhibition of FKBP12cy with FK506 [dissolved in 50% (v/v) aqueous ethanol] was determined in the range 4.7 0C-20 0C as described in the caption to Figure   2 . The activation enthalpy AH$ was calculated to be 67+12 kJ mol-1.
isomer with respect to the a-ketoacyl-pipecolinyl moiety is mainly in the trans form, rendering rearrangement unnecessary when binding occurs. Furthermore, rapamycin does not form tautomers after transfer into different solvent conditions as was shown for FK506 (Namiki et al., 1993) . Since the rate of this tautomerization approaches a time-scale related to those obtained for the slow phase of the inactivation of FKBPs it was advisable to check the importance of this effect with regard to the kinetic pattern of inhibition. Like FK506, rapamycin inhibits FKBP12cy in a two-phase process (Figure 2 ). For practical reasons, the inactivation reaction was carried out at 15 'C. At 10 'C the plateau region of inhibition had not yet been achieved after 120 min, which led to irregularities due to the loss of PPIase activity by adsorption on the surface of the reaction vessel, indicated by the reference reaction lacking inhibitor. Under these conditions we determined kobs = (6.1 + 0.9) x 10-s-I and r = 3.6, corresponding to a predominance of the high-affinity binding conformation of rapamycin in the organic stock solution.
Temperature-and pH-dependence of the slow inhibition (Figure 4) , AH$ was found to be 67+ 12 kJ mol-1. This value is located within the range of the uncatalysed rotational barrier of the cis-trans isomerization of Xaa-Pro bonds (Brandts et al., 1975: [AHt = 84 + 12 kJ mol-1; Fischer et al., 1983 : AHtGlyProNHNp = 66.9 kJ -mol-). Since a PPIase is involved in the inactivation reaction, the AH: value of the enzyme catalysed prolyl bond-isomerization is also of interest. However the fact that with CyPs and FKBP12cy the magnitude of AHt does not exceed 20 kJ mol-h, regardless of either kcat.
(G. Fischer, unpublished work) or kcat./Km (Stein, 1993) , was investigated.
The reversible hydration or the formation and decomposition of hemiacetals thought to be involved in the tautomerization of FK506 (Namiki et al., 1993) are usually subject to general acid-base catalysis (Jencks, 1969) . pH-dependent rate constants would therefore be indicative of proton transfer reactions on the reaction pathway. We examined the kinetics of the FK506-FKBP12cy interaction as a function of pH in the range 6.0-9.5 at 10 'C. In fact, pH had no influence on inhibition kinetics (Table 2) . Therefore, any tautomerization or hydration/ dehydration within the tricarbonyl stretch of the peptidomacrolides can be ruled out as being the source of the slow inactivation process.
DISCUSSION
Contrary to present knowledge, by detailed analysis of the kinetics of inhibition of FKBPs by FK506, ascomycin and rapamycin, we were able to detect a rather slow phase of inactivation upon preincubation of the reactants. In all cases the inhibition clearly occurs in two phases, a rather slow first-order process dominating in its amplitude subsequent to a fast reaction of inactivation still remaining unresolved in its time-course. Additionally, the increase of the inhibitory potency of FK506 during preincubation results in a 2.6-fold decrease in the inhibition constant Ki in comparison to the initial value. This may explain the variance in the K, values reported, ranging from 1.7 nM initial values (Harrison and Stein, 1990) to 0.4 nM (Yang et al., 1993 ) after a few minutes (not clearly defined) of preincubation.
As a consequence of the experiments it became clear that the peptidomacrolides strongly resemble CsA in the time-course of their interaction with PPlases. However, in contrast to the cyclosporins, for peptidomacrolides detailed knowledge of the conformational heterogeneity in most of the polar solvents is still lacking. For FK506 in CDC13 there is a 2:1 excess of the cis conformer over the trans pipecolinyl bond. For rapamycin, 80 % trans isomers are present in CDC13, increasing in DMSO to 90 % (Kessler et al., 1993) . Low solubility prevents n.m.r. spectroscopic investigations in aqueous systems. Besides amide bond rotation, a further conformational peculiarity of the FK506 region interacting with the active site of FKBP12cy might be important. In unconstrained a-dicarbonyl derivatives the carbonyl groups usually adopt an anti orientation (Mobilio et al., 1991) . The cis conformer in CDC13 (Karuso et al., 1990) or in the crystal presents the a-dicarbonyl moiety in an approximately orthogonal orientation as can also be found for the trans conformer in the FKBP12cy complex. However, the imidic bond itself provides the scaffolding effect for the a-ketoamide moiety, rendering it unnecessary for strain to be applied from either the protein or the macrocycles. On the HF/6-31G(d) computational level, N,Ndimethylpyruvamide served as the model system to provide parameters for the flexibility of the binding-region of peptidomacrolides (Bach et al., 1993 r-parably high torsional barriers for both OC-CO and C-N bond rotation.
From the results presented above, it seems likely that the slow inactivation process, although monomolecular in its kinetics, does not occur on the enzyme-inhibitor molecule, as is thought to be the case in the Cypl8cy-CsA complex, but is a nonenzymic event that arises from a reaction of the unbound peptidomacrolides. Consequently, a sort of suicide inhibition characterized by the trapping of an intermediate of the catalytic pathway is less probable. Substitution of proline in oligopeptide substrates by pipecolinic acid correlates with this finding, because the modified oligopeptides cannot be catalytically utilized by PPlases (G. Fischer, unpublished work) .
Among the monomolecular rearrangements possibly occurring in the inhibitor molecules the cis-trans isomerization of the aketoacyl pipecolinyl bond provides a convincing candidate for this process. Both the measured activation enthalpy, which is typical for prolyl-peptide bond isomerization, and the knowledge about the conformation of the bound peptidomacrolide, provide convincing evidence that the OC-CO rotation should not be involved in the slow inactivation. It was also evident from the pH-independence of the kinetics and the rapamycin experiment that tautomerization does not contribute to slow phases of inhibition. Thus, a minimal kinetic scheme for the inactivation process is shown in eqn. (2) (2) where kt and kt, are the first order rate constants for cis-trans and trans-cis isomerization respectively.
In this case the amplitude ratio r can be directly assigned to the equilibrium constant of isomerization which thus becomes available for aqueous solution. By this criterion the order FK506 ascomycin > rapamycin was found for the cis content, which accords with values in CDCl3 solution.
The above considerations are emphasized by the time-dependent uptake of [Arg32]ascomycin by FKBP12cy from an aqueous solution, since the addition of FKBP12cy selectively depletes the trans conformer. The rate constant for the cis to trans interconversion was estimated to be 2.4 x 1O-4 s-' at 12°C (Petros et al., 1993) , which is slightly lower compared with the same parameter of unsubstituted ascomycin and FK506 given above.
In conclusion, there is ample evidence that the biphasic inhibition process monitored during the interaction of peptidomacrolides with FKBPs is caused by the uncatalysed cis to trans isomerization of the a-ketoacyl pipecolinyl bond of the unbound molecules. There was no sign of a reshuffling of the bound trans isomer to a more bioactive conformation. However, both processes, the time-dependent formation of an increasing amount of the complex and the slow decrease of residual enzymic activity observed concomitantly, should be taken into consideration in biological assays. It is clear that at high intracellular concentrations of FKBPs and for assays working in the time-scale of the inactivation process, these effects could have a particular influence.
